Armis Advisers LLC purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 755 shares of the company's stock, valued at approximately $583,000.
Several other institutional investors and hedge funds also recently modified their holdings of the business. Chokshi & Queen Wealth Advisors Inc bought a new position in shares of Eli Lilly and Company in the fourth quarter worth $741,000. Garde Capital Inc. lifted its holdings in shares of Eli Lilly and Company by 22.7% in the fourth quarter. Garde Capital Inc. now owns 1,107 shares of the company's stock valued at $855,000 after buying an additional 205 shares during the period. Wilkins Miller Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $421,000. Liberty Square Wealth Partners LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at $594,000. Finally, Great Valley Advisor Group Inc. lifted its holdings in shares of Eli Lilly and Company by 7.2% in the fourth quarter. Great Valley Advisor Group Inc. now owns 24,756 shares of the company's stock valued at $19,111,000 after buying an additional 1,662 shares during the period. Institutional investors own 82.53% of the company's stock.
Insider Activity at Eli Lilly and Company
In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Several analysts have recently weighed in on LLY shares. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. UBS Group cut their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price for the company. Citigroup reduced their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Finally, Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $1,011.37.
Get Our Latest Stock Analysis on LLY
Eli Lilly and Company Stock Down 0.9%
Shares of NYSE LLY traded down $6.63 during mid-day trading on Wednesday, reaching $718.59. 2,929,417 shares of the company traded hands, compared to its average volume of 3,620,321. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market cap of $681.03 billion, a PE ratio of 61.37, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company's fifty day moving average is $784.45 and its two-hundred day moving average is $801.86. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business's revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.58 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.
Eli Lilly and Company Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.83%. Eli Lilly and Company's payout ratio is 48.82%.
Eli Lilly and Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles

Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.